Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 May;23(5):961-968.
doi: 10.1007/s12094-020-02545-x. Epub 2021 Jan 30.

SEOM clinical guideline in ovarian cancer (2020)

A Redondo  1 , E Guerra  2 , L Manso  3 , C Martin-Lorente  4 , J Martinez-Garcia  5 , J A Perez-Fidalgo  6 , M Q Varela  7 , M J Rubio  8 , M P Barretina-Ginesta  9 , A Gonzalez-Martin  10
Affiliations
Practice Guideline

SEOM clinical guideline in ovarian cancer (2020)

A Redondo et al. Clin Transl Oncol. 2021 May.

Abstract

Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer. In the last decade, there have been important advances both in systemic and surgical treatment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.

Keywords: Diagnosis; Guideline; Ovarian cancer; Treatment.

PubMed Disclaimer

Conflict of interest statement

AR reports honoraria and advisory/consultancy (MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar, Lilly, Amgen), research grant/funding to his institution (Eisai, PharmaMar, Roche), travel/accommodation/expenses (AstraZeneca, Tesaro: A GSK Company, PharmaMar, Roche), and speakers bureau (MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar), outside the submitted work. EG has received advisory/consultancy honorarium from AstraZeneca-MSD, Clovis Oncology, GSK-Tesaro, PharmaMar, Roche; has received speaker bureau/expert testimony honorarium from AstraZeneca, PharmaMar, Roche, GSK; and has received travel/accommodation/expenses from Roche, TESARO: A GSK Company and Baxter. LM has received advisory/consultancy honorarium from AstraZeneca, Clovis Oncology, Genmab, GSK, Merck Sharp & Dohme, Novartis, Pfizer/Merck, PharmaMar, Roche; has received speaker bureau/expert testimony honorarium from AstraZeneca, PharmaMar, Roche, GSK, Roche; has received research grant/funding from TESARO: A GSK Company; and has received travel/accommodation/expenses from AstraZeneca, Novartis, Roche, TESARO: A GSK Company. CML reports honoraria and advisory/consultancy (AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar, Roche); travel/accommodation/expenses (AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar, Roche); and speakers bureau (AstraZeneca, Clovis Oncology, GSK, MSD, PharmaMar, Roche). JMG has served on Advisory for PharmaMar, GSK and Amgen; travel and accommodation from PharmaMar and GSK. JAPF declares advisory board: Roche, Astrazeneca, GSK, Clovis, Pharmamar, Abilify Pharma, Amgen; Travel/Expenses: Roche, Astrazeneca, Pfizer, GSK; Speaker: Roche, Astrazeneca, GSK, Clovis, Pharmamar, Novartis; Institutional support: GSK, Novartis. MQV reports honoraria and advisory/Consultancy from AstraZeneca, GSK, MerckSharp & Dohme, Novartis, PharmaMar, Roche, Bristol-Myers Squibb,Pierre Fabre; Travel/Accommodation/Expenses from AstraZeneca, Pharmamar, Roche, GSK, Merck Sharp&Dohme and speakers bureau AstraZeneca, GSK, MerckSharp & Dohme, Novartis, PharmaMar, Roche, Bristol-Myers Squibb, Pierre-fabre. MJR has served on advisory boards for MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar and received support for travel or accommodation from Roche, AstraZeneca, and PharmaMar. MPBG has served on Advisory boards for Roche, AstraZeneca, PharmaMar, Clovis Oncology, GSK, Merck Sharp & Dohme; has received speaker bureau honoraria from AstraZeneca, Roche, PharmaMar, GSK, Clovis Oncology, Merck Sharp & Dohme and received support for travel or accommodation from Roche, AstraZeneca, GSK and PharmaMar. AGM reports honoraria and advisory/Consultancy: Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, Novartis, Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio; Speaker Bureau: AstraZeneca, PharmaMar, Roche, GSK; Research Grant/Funding: Roche, TESARO: A GSK Company and Travel/Accommodation/Expenses: AstraZeneca, Pharmamar Roche, TESARO: A GSK Company.

References

    1. Prat J, FIGO Committee on Gynecologic Oncology Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Oncol. 2014;124:1–5. - PubMed
    1. Kobel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35:430–441. doi: 10.1097/PGP.0000000000000274. - DOI - PMC - PubMed
    1. Park HJ, Kim DW, Yim GW, et al. Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. Am J Obstet Gynecol. 2013;209(58):e1. doi: 10.1016/j.ajog.2013.08.026. - DOI - PubMed
    1. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672–705. doi: 10.1093/annonc/mdz062. - DOI - PubMed
    1. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Eng J Med. 2019;380:822–832. doi: 10.1056/NEJMoa1808424. - DOI - PubMed

Publication types

MeSH terms

Substances